SCHEMBL13087296

SCHEMBL13087296

N#Cc1cccc(-c2cc(NC3CCN(S(=O)(=O)Cc4ccccc4)CC3)c3cnccc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 5/20 0.46
ROCK1 Q13464 1/20 0.40
CCR6 P51684 1/20 0.39
PRKCZ Q05513 4/20 0.39
PRKD2 Q9BZL6 3/20 0.39
IKBKB O14920 2/20 0.39
CHUK O15111 2/20 0.39
PTPN1 P18031 4/20 0.39
CYP2C9 P11712 2/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
PTPRC P08575 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087712 0.91 ROCK2 (0.45) ROCK2ROCK1CCR6PRKCZPRKD2
SCHEMBL13087153 0.88 CCR6 (0.51) ROCK2CCR6PRKCZPRKD2
SCHEMBL2424533 0.87 ROCK2 (0.43) ROCK2CCR6PRKCZPRKD2
SCHEMBL13089969 0.87 ROCK2 (0.43) ROCK2CCR6PRKCZPRKD2CYP1A2
SCHEMBL13089944 0.86 CCR6 (0.42) ROCK2CCR6PRKCZPRKD2
SCHEMBL13090008 0.84 CCR6 (0.51) ROCK2CCR6IKBKBCHUK
SCHEMBL13087706 0.84 ROCK2 (0.42) ROCK2ROCK1CCR6PRKCZPRKD2
SCHEMBL13087793 0.84 CDK2 (0.44) ROCK2CCR6PRKCZPRKD2
SCHEMBL13087245 0.84 CCR6 (0.44) ROCK2CCR6ALDH1A1TSHR
SCHEMBL13087792 0.84 PIK3CA (0.42) ROCK2CCR6PRKCZPRKD2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 ROCK2 1065/4885ROCK1 745/4885CCR6 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.